Global Plasma Fractionation Market Report and Forecast 2024-2032

Global Plasma Fractionation Market Outlook

The global plasma fractionation market value was USD 27.96 billion in 2023, driven by the growing demand for plasma-derived therapies across the globe. The market size is anticipated to grow at a CAGR of 6.7% during the forecast period of 2024-2032 to achieve a value of USD 50.11 billion by 2032.

Key Trends in the Market

Plasma fractionation is the process of breaking down and separating the different components of blood plasma collected from donors. The proteins separated from the plasma are used as a therapeutic product for prevention and treatment of life-threatening diseases such as immunological disorders, blood clotting disorders, and others.

• Respiratory diseases along with AATD (Alpha-1-antitrypsin deficiency) are increasing and becoming widely prevalent. More people are undergoing therapy for treatment of such disease which is contributing to the growth of the market globally. AATD is an unrecognised chronic metabolic genetic disorder which can also cause emphysema.

• Bleeding disorders such as haemophilia have been rising which are characterised by impaired blood coagulation. One of the main applications of plasma fractionation is the treatment of haemophilia which is helping in the growth of the plasma fractionation market.

• Plasma collection centres are spread all over the world in large numbers so that human plasma that can be used for treatment of more individuals without facing shortages. Post-collection, there is need for plasma fractionation, making it a key trend for the market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Analysis

Based on product, the plasma fractionation market can be segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and others. On the basis of application, it can be divided into neurology, immunology, haematology, rheumatology, and others. Based on processing technology it is divided into ion exchange chromatography, affinity chromatography, cryopreservation, ultrafiltration, and microfiltration. By end use the market is divided into hospitals and clinics, clinical research laboratories, academic institutes, and others. On a regional basis, the market can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East, and Africa.

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global plasma fractionation market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

• CSL Plasma LLC

• Grifols, S.A.

• Takeda Pharmaceutical Company Limited

• Biotest Group

• Baxter International Inc.

• Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Share by Product Type

Immunoglobulins hold a significant share in the market for plasma fractionation because of their ability to treat autoimmune diseases and increase immune response. Coagulation factor concentrates help in the formation of blood clots whereas albumin is involved in the movement of molecules through blood. HIV progression is slowed down with the help of protease inhibitors. All these products largely contribute to the growth of the market.\

Market Share by End Use

Improved infrastructure and facilities in hospitals have made it the largest shareholder in the market for plasma fractionation. Hospitals and clinics are now providing treatment facilities for various autoimmune diseases using plasma products which is why it is predicted to dominate the market in the forecast period as well. Clinical research laboratories are also researching for new and innovative therapy techniques, contributing to the growth of the plasma fractionation market.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape 

CSL Plasma LLC was founded in 1916 and has its headquarter in Florida, United States. Its parent company CSL Behring makes use of human plasma to treat bleeding disorders, neurological disorders, immune deficiency, inherited respiratory disease, and hereditary angioedema.

Grifols S.A. was founded in 1940. Based out of Barcelona, Spain, it is a Spanish company specialising in the manufacture of pharmaceuticals and chemicals. It mainly produces blood plasma-based products among other instruments, and reagents to be used in clinical testing.

Biotest Group is known globally for developing and supplying biotherapeutic drugs and plasma protein products. It was established in 1946 and has its headquarter in Dreieich, Germany.

Other market players include Takeda Pharmaceutical Company Limited, and Baxter International Inc., among others.

Key Highlights of the Report